Company: ACBM
Filing Date: 2025-07-23
Form Type: 10-Q
Source: 0001640334-25-001281
Chunk: 1

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-23
Form: 10-Q
Item: Item 1
Chunk 1
---
$-  $-  $-  $-                  Operating expenses                Selling, general and administrative   9,106   700,150   28,490   3,500,141 Research and development  -   396,550   -   4,794,825 Provision for doubtful accounts  -   480,000   -   480,000 Provision for purchase deposit write-off  -   12,000   -   12,000 Total operating expenses  9,106   1,588,700   28,490   8,786,966                  Loss from operations  (9,106)  (1,588,700)  (28,490)  (8,786,966)                 Other expense                Interest expense - related party  1,123   790   3,134   2,367 Total other expenses  1,123   790   3,134   2,367                  Loss before income tax expense  (10,229)  (1,589,490)  (31,624)  (8,789,333)Income tax expense  -   -   -   - Net loss $(10,229) $(1,589,490) $(31,624) $(8,789,333)                 Basic and diluted loss per share of common stock $(0.00) $(0.03) $(0.00) $(0.15)                 Weighted average number of shares of common stock outstanding  60,042,000   60,042,000   60,042,000   60,042,000 

The accompanying notes are an integral part of these unaudited financial statements.

 5Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Changes in Stockholders’ Equity (Deficit)

(Unaudited)

For the Three and Nine months ended September 30, 2024

              Additional     Total   Preferred Stock  Common Stock   Paid in   Accumulated  Stockholders'     Shares    Amount    Shares